Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26940380 | 0.83 | ALDH1A1 (0.50) | POLBKDM4ELMNACNR2ALDH1A1 | |
| SCHEMBL3875250 | 0.83 | ALDH1A1 (0.59) | POLBKDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL9008078 | 0.79 | POLB (0.47) | POLBKDM4ELMNAHSD17B13CNR2 | |
| SCHEMBL4469156 | 0.78 | CNR2 (0.49) | POLBKDM4ECNR2ALDH1A1BCHE | |
| SCHEMBL20942675 | 0.78 | POLB (0.46) | POLBKDM4ELMNAHSD17B13ALDH1A1 | |
| SCHEMBL15458739 | 0.78 | KMT2A (0.62) | POLBKDM4ELMNAHSD17B13CNR2 | |
| SCHEMBL11837808 | 0.77 | POLB (0.64) | POLBKDM4ELMNAALDH1A1MAPT | |
| SCHEMBL2329963 | 0.76 | ALDH1A1 (0.47) | POLBKDM4EALDH1A1MAPTGAA | |
| SCHEMBL4767726 | 0.75 | CNR2 (0.57) | POLBKDM4ECNR2ALDH1A1KMT2A | |
| SCHEMBL26943125 | 0.75 | HSD17B13 (0.56) | POLBKDM4ELMNAHSD17B13CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| EP-2935278-B1 | TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL | NOVARTIS AG (CH) | 2017-03-15 | — | — | EP | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| US-9359381-B2 | Tricyclic compounds for inhibiting the CFTR channel | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20150336986-A1 | TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL | NOVARTIS AG (CH) | 2015-11-26 | — | — | US | disclosed |
| US-20140171417-A1 | TRICYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | POLB 1001/4885KDM4E 3386/4885LMNA 4664/4885 |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | RORB, RORC, RORA | POLB 4084/4885KDM4E 728/4885LMNA 4161/4885 |
| US-20150336986-A1 | TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL | CFTR, SLC26A4, ABCB11 | POLB 2449/4885KDM4E 4640/4885LMNA 2962/4885 |
| US-20140171417-A1 | TRICYCLIC COMPOUNDS | SLC10A1, CYP11B2, CYP11B1 | POLB 3924/4885KDM4E 3834/4885LMNA 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.